- Patient Presentation
- Differential Diagnosis
- Final Outcome
- Evaluation - Questions & answers
A 32 year old female presented to the emergency room with a two month history of worsening dyspnea, cough with production of sputum, haemoptysis and extensive weight loss. At the time of presentation she was wasted and in moderate respiratory distress.
- Known RVD positive.
- Diagnosed three years previously but not on ARV’s. Lost to follow-up since initial diagnosis.
Past medical history
- RVD positive
Past surgical history
- Nothing of significance
- Nil known
- 6 pack year history of smoking, stopped 3 years ago
- No ethanol use
- No recreational drugs
- Community acquired pneumonia
- Kaposi Sarcoma
- Awake and alert, ill-looking wasted female
- Temperature: 38oC
- Blood pressure:110/70
- Heart rate: 100
- Respiratory rate: 36 breaths per minute
- Conjunctival pallor
- Cervical, axillary and inguinal lymphadenopathy
- Raised purple nodule on palate, 4cm in length
- Crackles bilaterally
- Not distended
- Soft, no generalised tenderness
- No organomegally
- Bowel sounds present
- Two violaceous plaques, non tender, 2cm in diameter on the upper back.
|WCC||5||4-12x10 9 /L|
|Platelets||138||140-450x10 9 /L|
|Arterial Blood Gas|
|pH||7.4||7.35 - 7.45|
|PCO 2||33.8 mmHg||35-45 mmHg|
|PO 2||52.2 mmHg||80 - 100 mm Hg|
|O 2 sats||89.3|
Chest X ray:
- Diffuse reticular nodular infiltrate
- Peri-hilar interstitial infiltrates bilaterally
- Left sided pleural effusion
- Peri-bronchovascular interstitial thickening
- Multiple small nodules in parenchyma of both lungs
- Thickening of interlobular septa
- Hilar lymphadenopathy
- Small left pleural effusion
- TB negative X3
Biopsy of lesion on palate
- Macroscopic: Specimen consists of a nodular fragment of mucosa-covered tissue with a blue appearance, measuring 11 x 6 x 4mm
- Microscopic: fragments of squamous mucosa covered tissue showing ectatic, slit-like vascular spaces surrounded by a spindle cell proliferation admixed with plasma cells and extravascated red blood cells. Scattered neutrophils are also seen and hyaline globules are present. The overlying mucosa is reactive.
Features are consistent with Kaposi sarcoma.
- HHV8-positive, nuclear dot-like staining.
Open lung biopsy:
- Typical histologic findings of Kaposi sarcoma (as described above)- indicating Pulmonary Kaposi Sarcoma (KS)
This patient was diagnosed with Kaposi’s sarcoma (KS), which is a spindle cell, angioproliferative, tumour-like lesion that typically develops in the skin, eventually disseminating to multiple cutaneous sites, viscera and lymph nodes. Initially a rare disease, it has increased in prevalence globally because of its association with HIV. In this discussion, we will outline the types of KS, the intrinsic association with human herpes virus type 8 and the immunology behind the development of lesions.
Four clinically relevant and different types of KS have been identified:
- Classical or sporadic KS, originally described as an indolent tumor in the extremities of elderly males of eastern and Mediterranean Europe.
- Endemic KS, predominant in eastern and central sub-Saharan Africa before the AIDS epidemic and clinically similar to Classical KS, but also seen in a more fulminant and fatal form in children.
- AIDS associated KS, the most frequent tumor of HIV-I infection and the most aggressive and rapidly growing form of KS, with early dissemination to the skin and viscera.
- Iatrogenic KS, seen in drug related immunosuppressed patients, e.g. transplant patients.
In spite of the clear clinical differences, all forms of KS are associated with human herpes virus type 8 (HHV-8) also known as Kaposi sarcoma-associated herpesvirus (KSHV). Other diseases associated with KSHV include primary effusion lymphoma or body-cavity-based-lymphoma (PEL/BCBL) found in AIDS patients and Multicentric Castleman’s disease (not discussed here).
This discussion will look at KSHV in immunocompetent patients and in the setting of immunocompromised patients, such as people with HIV, which is likely occurring in our patient. We will also explore the adaptations that make this virus so efficient in circumventing the immune system. Lastly we will discuss the infection of endothelial cells, with their subsequent transformation and proliferation into spindle cells and the development of KS lesions.
Signs and symptoms of Kaposi Sarcoma
Lesions in KS may involve the skin, oral mucosa, lymph nodes, and visceral organs. Most patients present with cutaneous disease. Visceral disease may occasionally precede cutaneous manifestations.
Cutaneous lesions in Kaposi sarcoma are characterized as follows:
- Cutaneous lesions may occur at any location but are usually found on the lower extremities and the head and neck region
- Lesions may have macular, papular, nodular, or plaquelike appearances
- Nearly all lesions are palpable and nonpruritic
- Lesions may range in size from several millimeters to several centimeters in diameter
- Lesions may assume a brown, pink, red, or violaceous color and may be difficult to distinguish in dark-skinned individuals
- Lesions may be discrete or confluent and typically appear in a linear, symmetrical distribution.
- Mucous membrane involvement is common (palate, gingiva, conjunctiva)
KS lesions may also develop in internal organs such as lung and GIT. This disseminated disease is associated with a greater degree of immunosuppression. Signs and symptoms of GIT involvement can include the following:
- Odynophagia, dysphagia
- Nausea, vomiting, abdominal pain
- Hematemesis, hematochezia, melena
- Bowel obstruction
Pulmonary lesions are usually associated with advanced immune-suppression and although they may occasionally be an asymptomatic radiographic finding, it is usually associated with evidence of respiratory disease, including:
- Respiratory failure
Overview of primary Human Herpes Virus type 8 (HHV-8) infection
To better understand HHV-8 infection we need to first look at how humans become infected with the virus and the viral replication cycle in the cell. HHV-8 or KSHV is a gamma herpesvirus which is primarily transmitted through saliva. Following infection, the virus establishes a life-long persistent infection in the new host as a result of multiple immune evasion mechanisms. The virus initially replicates in epithelial cells and B cells of the oropharynx and subsequently targets B cells, the primary viral reservoir. Infection by HHV8 results in one of two infection states in the cell. This is depicted in graphic 1. In lytic infection, many viral genes are expressed, the cell makes new virus particles and it dies after a short time period. In latent infection, only a few viral genes are expressed. This limited gene expression enables the infected cell to escape immune surveillance and survive long term.
Latently infected B cells then travel to different areas around the body. Those that traffic to lymphoid tissues may be triggered into the lytic replication cycle by various signals such as inflammation. Lytically infected B cells are thought to promote infection of other cell types such as endothelial cells. Infected hosts will typically remain asymptomatic provided their immune system is intact, but may shed virus asymptomatically in saliva from time to time. In our case study, the patient has an immunocompromised immune system, due to HIV infection, and thus her ability to control HHV-8 is poor. HHV-8 infection of endothelial cells is necessary for the development of Kaposi sarcoma.
Normal immune control of HHV-8 infection
HHV-8 can use alternative receptors, including heparin sulphate, a3b1 integrin and DC-SIGN, to gain entry into target cells. As decribed, the target cells are primarily B cells but the virus can also infect epithelial and endothelial cells. Once infected, most B cells are latently infected, containing episomal copies of viral DNA which expresses a minimal set of viral genes needed to maintain the viral episomes and prevent activation of the lytic cycle. These minimal viral genes are depicted in graphic 2 as Kaposin, vFLIP, vCyclin, LANA, vIL-6 and K1.
The lytic cycle may be activated by external events such as immune activation of the B cell via B cell receptor (BCR) stimulation or interaction with CD4+ helper T cells. Latent viral proteins normally inhibit the activation of infected B cells. Viral genes transcribed during both latent and lytic replication cycles subvert innate and adaptive anti-viral immune responses. HHV-8 infection of vascular endothelial cells transforms them and causes them to adopt a spindle cell morphology (through the action of latency associated genes). These spindle cells produce cytokines which cause them to proliferate and under normal conditions this proliferation is well controlled.
The process of infection of endothelial cells in an immunocompromised host will be described in the next slides
HHV-8 infection of endothelial cells
When the immune system is compromised a common manifestation of HHV-8 infection is the development of malignant lesions in the skin, although involvement of mucosal or visceral sites are also possible. It is thought that these lesions develop when vascular endothelial cells in skin capillaries become infected with HHV-8. Which occurs by direct infection of capillary endothelial cells or via circulating infected endothelial progenitor cells. In immunocompetent individuals, HHV-8 infection remains asymptomatic because viral replication is controlled and existing virus escapes detection by remaining in latent form. However, if HIV infection occurs or immunosuppressive therapy is introduced, reactivation of latent virus is increased leading to increased infection of endothelial cells.
Transformation of HHV-8 infected endothelial cells
Infection of endothelial cells leads to their transformation and proliferation by virus encoded gene products. Invasion of the subendothelial cell layer, such as the dermis of the skin, occurs. Proliferation of spindle cells is mainly driven by cytokine stimulation. Viral cytokines produced by virus-infected cells such as viral (v) IL-6, a homologue molecule of human IL-6, stimulates the production of vascular endothelial growth factor (VEGF). Viral IL-6, is able to bind to the gp130 chain of the human IL-6 receptor, but does not need to bind the co-receptor to exert its activity. Because of this the vIL-6 acts on a wider range of target cells (although it is intrinsically less active than the human protein).
The virus also expresses a constitutively active homologue of the IL-8 receptor, known as viral GPCR, which is a key protein in the KS disease process. It is expressed in lytically infected cells. It activates intracellular signaling pathways (in the same cell expressing it) to induce production of a battery of cytokines including: IL-8, IL-6, IL-1b, TNFa, bFGF and VEGF. The secretion of VEGF is a primary driver of endothelial cell proliferation via the VEGF receptor. Most of the proliferating cells are latently infected with HHV-8 and develop into characteristic spindle cells.
Formation of a Kaposi Sarcoma lesion
The formation of a KS lesion is due to the increased proliferation of latentlly infected spindle cells. This is driven by low numbers of HHV-8 infected cells that are in the lytic phase. The cytokines produced by these cells, particularly VEGF and vIL-6 drive the other spindle cells to proliferate (by para-crine oncogenesis). VEGF promotes additional angiogenesis that supplies oxygen and nutrients to the tumour cells. Increased vascularisation and trapping of extravasated red cells in spaces between the spindle cells leads to the characteristic red colour of the lesions. Infiltration of immune cells such as T cells, plasma cells and macrophages, is also a consequence of chemokine release from lytic infected cells. Viral chemokines that are homologues of human CCL1,-2 and -3 contribute to the chemotaxis of immune cells to the site of the lesion.
A feature of the formation of KS lesions is Paracrine neoplasia:
KS is not a mono-clonal malignancy. Rather, it is the result of polyclonal proliferation of virus infected spindle cells. This process is driven by viral genes, most of which are expressed in lytically infected cells. In an early KS lesion, most of the proliferating spindle cells are latently infected. Occasional lytically infected cells secrete key cytokines that act in a para-crine fashion to drive the surrounding cells to proliferate further, recruit inflammatory cells to the lesion and induce angiogenesis.
Kaposi sarcoma lesions develop in the skin at late stages of HHV-8 reactivation, following failure of the immune system to control virus replication. Widespread dissemination to the viscera and mucosa may also occur. Thus when our patient was diagnosed with pulmonary KS, it was indicative of systemic disease and explained her symptoms such as fever, drenching night sweats and weight loss. These cytokine driven responses are always a poor prognostic sign.
- Following admission this patient was started on empiric TB therapy.
- First-line ARVs were initiated – 3TC, Tenofovir and efavirenz. (If a patient has non visceral disease HAART may be tried as the sole treatment).
- Due to the presence of visceral disease this patient was also referred for chemotherapy: vincristine, doxorubicin and bleomycin.
Although local therapy was not administered to this patient, the following local therapies can be used for locally advanced disease of in patients with cosmeticaly unacceptabe lesions, including:
- Radiation therapy
- Laser therapy
- Surgical excision
- Intralesional vinca alkaloid therapy
- Topical retinoids
The patient experienced a severe episode of haemoptysis, and died from uncontrolled pulmonary haemorrhage.
Pulmonary involvement is the most common cause of mortality in these patients.
Pyakurel P et al (2007). KSHV/HHV-8 and HIV infection in Kaposi’s sarcoma development. Infect Agent Cancer. Feb 2;2:4.
Sathish N et al (2011) Evasion and subversion of interferon-mediated antiviral immunity by Kaposi’s sarcoma-associated herpesvirus: an overview., J Virol. Nov;85(21):10934-44.
Dittmer DP et al (2013) Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)-an update., Curr Opin Virol. Jun;3(3):238-44.
Ruocco E et al (2013). Kaposi’s sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: Facts and controversies.,Clin Dermatol. Jul-Aug;31(4):413-22
Mesri EA et al (2010) Kaposi’s sarcoma and its associated herpesvirus.,Nat Rev Cancer. Oct;10(10):707-19.
Dimaio TA et al (2012) KSHV Induction of Angiogenic and Lymphangiogenic Phenotypes., Front Microbiol. Mar 30;3:102
Montaner S et al (2013) Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases., Annu Rev Pharmacol Toxicol. 53:331-54
Evaluation – Questions & answers
What is the diagnosis?
What is the causative organism associated with Kaposi sarcoma?
What are the target cells for this infection?
In what two forms does the virus exist?
What is the benefit of viral latency?
What is the benefit of the lytic phase?
How do Kaposi Sarcoma lesions form?
Why are Kaposi Sarcoma lesions red in colour?
What is a poor prognostic sign of KS?
Test your knowledge – Online Quiz